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ABSTRACT 23 
Cachexia, the most severe paraneoplastic syndrome, occurs in about 80% of patients with advanced 24 
cancer; it cannot be reverted by conventional, enteral, or parenteral nutrition. For this reason, 25 
nutritional interventions must be based on the use of substances possessing, alongside nutritional 26 
and energetic properties, the ability to modulate production of the pro-inflammatory factors 27 
responsible for the metabolic changes characterising cancer cachexia. In light of their nutritional 28 
and anti-inflammatory properties, polyunsaturated fatty acids (PUFAs), and in particular n-3, have 29 
been investigated for treating cachexia; however, the results have been contradictory. 30 
Since both n-3 and n-6 PUFAs can affect cell functions in several ways, this research investigated 31 
the possibility that the effects of both n-3 and n-6 PUFAs could be mediated by their major 32 
aldehydic products of lipid peroxidation, 4-hydroxyhexenal (HHE) and 4-hydroxynonenal (HNE), 33 
and by their anti-inflammatory properties. An “in vitro” cancer cachexia model, consisting of 34 
human lung cancer cells (A427) and murine myoblasts (C2C12), was used. 35 
The results showed that: 1) both n-3 and n-6 PUFAs reduced the growth of lung cancer cells 36 
without causing cell death, increased lipid peroxidation and Peroxisome Proliferator-Activated 37 
Receptor (PPAR)α, and decreased TNFα; 2) culture medium conditioned by A427 cells grown in 38 
the absence of PUFAs blocked myosin production and the differentiation of C2C12 muscle cells; 39 
conversely, muscle cells grown in culture medium conditioned by the same cells in the presence of 40 
PUFAs showed myosin expression and formed myotubes; 3) adding HHE or HNE directly to 41 
C2C12 cells maintained in culture medium conditioned by A427 cells in the absence of PUFAs 42 
stimulated myosin production and myotube formation; 4) putative consensus sequences for 43 
(PPARs) have been found in genes encoding fast isoforms of myosin heavy chain, by a 44 
bioinformatics approach. 45 
The overall results show, first, the ability of both n-3 and n-6 PUFAs and their lipid peroxidation 46 
products to prevent the blocking of myosin expression and myotube formation caused in C2C12 47 
cells by medium conditioned by human lung tumor cells. The C2C12 cell differentiation can be due 48 
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to direct effect of lipid peroxidation products, as evidenced by treating C2C12 cells with HHE and 49 
HNE, and to the decrease of pro-inflammatory TNFα in A427 cell culture medium. The presence of 50 
consensus sequences for PPARs in genes encoding the fast isoforms of myosin heavy chain 51 
suggests that the effects of PUFAs, HHE, and HNE are PPAR-mediated. 52 
 53 
KEYWORDS: cachexia; lung cancer; muscle cells; n-3 PUFAs; n-6 PUFAs, lipid peroxidation; 54 
HHE; HNE; myosin; PPARs; PPRE; TNFα. 55 
 56 
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INTRODUCTION 58 
 59 
Cachexia is both the most common and the most severe paraneoplastic syndrome; it was recently 60 
defined as a multifactorial condition. It is chiefly characterised by loss of skeletal muscle mass, and 61 
negative protein and energy balance, driven by a variable combination of reduced food intake and 62 
abnormal metabolism that is not fully reversed by conventional nutrition. It leads to a reduction in 63 
the response and tolerance to therapy, and in the quality and duration of life [1]. Cachexia occurs in 64 
about 80% of patients with advanced cancer; its incidence and prevalence differ in relation to the 65 
type of cancer, the highest incidence being observed in pancreatic, gastric and lung cancer [2]. Lung 66 
cancer induces sarcopenia associated to malnutrition, with a relatively high frequency (above 50%). 67 
Depending on the cachexia classification, about 20% of patients with non small cell lung cancer 68 
(NSCLC) are diagnosed as cachectic, and about 25% as pre-cachectic [3-5]. Malnutrition, due in 69 
part to alterations in neurohormonal mechanisms controlling food intake, contributes to metabolic 70 
alterations leading to a negative energy balance. This, in association with altered protein turnover 71 
and inflammation, drives the muscle wasting characterizing cachexia to develop [6]. With regard to 72 
the metabolic modifications occurring in cachexia, several cytokines produced by both tumour and 73 
host (TNF-α, IL-6, IL-1, INF-γ) or by tumour alone (proteolysis-inducing factor, PIF, lipid 74 
mobilizing factor, LMF) have been identified as molecular mediators of cachexia [7,8]. 75 
Due to its multifactorial pathogenesis, cachexia is unaffected by conventional dietary interventions, 76 
and limited benefits have been demonstrated by enteral and parenteral nutrition [9,10]. For these 77 
reasons, nutritional interventions focused on the use of substances with both nutritional and anti-78 
inflammatory properties, with the aim of improving energy balance and reducing inflammatory 79 
status, have been proposed. In this perspective, and in light of their anti-inflammatory properties, 80 
fish-oil and its primary components, n-3 polyunsaturated fatty acids (PUFAs), have been proposed 81 
for treating cachexia. Moreover, in patients with cancer, a low concentration of n-3 PUFAs in the 82 
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plasma phospholipids has been shown at diagnosis, the value further declining during cancer 83 
progression [11-13]. 84 
Among n-3 PUFAs, eicosapentaenoic (EPA) and docosahexaenoic (DHA) acid have been shown to 85 
down-regulate production of pro-inflammatory cytokines and acute-phase proteins in cancer patient 86 
blood [14-18], although a recent systematic review on the role of fish oil in treating cachexia 87 
concluded that there is insufficient evidence of a net benefit of n-3 PUFAs in advanced cancer. 88 
However, the same study reported that n-3 PUFA treatment can be beneficial for some selected 89 
patient populations, acting as post-operative support able to improve wound healing and reduce 90 
complications [19].  91 
Different mechanisms have been postulated to explain the effect of n-3 PUFA, including 92 
modulation of the activity of some transcription factors, such as NFkB and PPARs, leading to a 93 
decreased production of pro-inflammatory cytokines and acute-phase proteins. Moreover, EPA has 94 
been reported to inhibit the activation of the ubiquitin-proteasome pathway induced by proteolysis-95 
inducing factor (PIF) and to decrease expression of the lipid mobilizing factor (LMF) [20,21]. More 96 
recently, EPA and DHA have been reported to affect the balance between anabolism and catabolism 97 
in muscles, through their effect on signalling transduction proteins and adipokines, in old and obese 98 
persons, thus suggesting another possible mechanism underlying n-3 PUFA-mediated anti-wasting 99 
effect [23,24]. 100 
The present research investigated the possibility that anti-cachectic properties of n-3 PUFAs could 101 
be mediated by the aldehydic products derived from their lipid peroxidation. 4-hydroxyhexenal 102 
(HHE) is the principal aldehyde generated by the non-enzymatic peroxidation of n-3 PUFAs. Due 103 
to its electrophilicity, HHE interacts strongly with cellular nucleophilic molecules, thus positively 104 
or negatively affecting several cell functions [22]. HHE-induced cytotoxicity has been reported in 105 
different cell types, including rat neurons and muscle cells, and human lens and renal epithelial 106 
cells. [25-29]. Moreover, the HHE concentration has been shown to be significantly higher in the 107 
hippocampus/parahippocampal gyrus of patients with preclinical and late-stage Alzheimer's disease, 108 
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than in that of normal subjects [30]. Conversely, it has recently been shown that, in some cases, 109 
lipoxidation of proteins can cause a gain of function/activity, suggesting that the formation of 110 
covalent protein/α,β-unsaturated aldehyde adducts, derived from lipid peroxidation, might be a step 111 
in a redox signalling pathway of physiological significance [31]. The present study was also based 112 
on a previous finding that, at a concentration found in many normal tissues and plasma, 4-113 
hydroxynonenal (HNE), the major lipid peroxidation product of n-6 PUFA, induced the 114 
differentiation of murine erythroleukemia MEL cells and human promyelocytic HL-60 cells, by 115 
modulating the expression of several genes involved in cell cycle control [32-34]. Moreover in 116 
some tumours, arachidonic acid (AA), a fatty acid belonging to n-6 PUFA, was shown to be present 117 
in a lower percentage in total fatty acids in comparison with corresponding normal tissues [35]. 118 
In this light, the research investigated the effect of both n-3 and n-6 PUFAs and their lipid 119 
peroxidation products (HHE and HNE) on muscle cell differentiation, using an “in vitro” cancer 120 
cachexia model, consisting of human lung cancer cells (A427) and murine myoblasts (C2C12). 121 
Moreover, to evidence the mechanisms underlying the effect of PUFAs on C2C12 cell 122 
differentiation, the expression of peroxisome proliferator activated receptor (PPAR) α and the 123 
release of TNFα were also evaluated in A427 cells and in their culture medium, respectively. 124 
Human lung cancer cells were chosen since, in lung cancer patients, cachexia is the main cause of 125 
death despite the improvement in anticancer therapies. Moreover, little is known about the effect of 126 
PUFAs on lung-cancer-induced cachexia. 127 
 128 
MATERIALS AND METHODS 129 
Treatment of A427cells with PUFAs 130 
Human lung adenocarcinoma cells A427 (ATCC, MD, USA) were seeded (20,000 cells/cm2) in 131 
DMEM/F12 medium with 2 mM glutamine, 1% antibiotic/antimycotic solution and 10% FBS 132 
(medium A). Twenty-four hours after seeding, medium A was replaced with medium B, containing 133 
DMEM/F12 medium, 2 mM glutamine, 1% antibiotic/antimycotic solution, 2% horse serum (HS), 134 
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and n-3 (EPA plus DHA) or n-6 PUFAs (AA) prepared in HS. EPA and DHA were administered 135 
simultaneously at a ratio of 1.5:1. For all treatments, the final concentrations were 10 or 50 µM. In 136 
control cells, a quantity of HS equivalent to the highest dose administered of PUFAs was added to 137 
the culture medium, in addition to the 2% HS already present in medium B. 138 
Twenty-four hours after addition of PUFAs or HS, culture media were collected and centrifuged at 139 
2800 g for 10 min (centrifuge J6B Beckman, CA, USA) at room temperature. The collected media 140 
were used to determine lactate dehydrogenase (LDH) release, and as conditioned medium to culture 141 
C2C12 cells. After removing media, A427 cells were detached with trypsin/EDTA (0.25%/0.03 142 
mM), centrifuged at 900 g for 10 min (centrifuge J6B Beckman, CA, USA) and used for the assays 143 
listed below. 144 
 145 
C2C12 cell culture conditions 146 
Murine muscle C2C12 cells (ATCC, MD, USA) were seeded at 6,000 cells/cm2 in medium A for 4 147 
days. After this time, to induce differentiation into myotubes, medium A was replaced with medium 148 
B, in which C2C12 cells were maintained for 3 further days. At the end of this period, medium B 149 
was replaced with medium conditioned by A427 cells, grown for 24 hours in the presence or 150 
absence of PUFAs. Cells were analyzed after a further 4 days. C2C12 cells maintained in medium B 151 
for a further 4 days were labelled “Tdiff”, and were taken as positive control. 152 
 153 
Treatment of C2C12 cells with HHE and HNE 154 
In these experiments, after removal of medium B (after 3 days), C2C12 cells were cultured in 155 
medium conditioned by A427 cells grown in the absence of PUFAs, and fortified with HNE or 156 
HHE at a concentration of 1 µM or 5 µM. The addition of 1 µM aldehyde was repeated every 45 157 
minutes up to 10 treatments (total amount 10 µM); in the case of 5 µM aldehyde, it was added as a 158 
single dose. C2C12 cells cultured in medium conditioned by A427 cells for 24 hours, in the absence 159 
of PUFAs, were used as control cells. C2C12 cells were analyzed after a further 4 days. 160 
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 161 
Cell growth and viability 162 
The numbers of A427 cells present in the monolayer and in the culture medium were evaluated by 163 
counting cells in a Burker chamber, and are expressed as cells/cm2. Cell viability was also evaluated 164 
in culture medium, as LDH release [36], and as DNA content after propidium iodide staining by 165 
using flow cytometry [37]. The viability of C2C12 cells during the different treatments was 166 
evaluated as LDH release. 167 
 168 
Immunofluorescence staining 169 
To evaluate the production of myosin and myotube formation, at the different experimental times 170 
C2C12 cells were washed with PBS, fixed with acetone/methanol (1:1) at -20°C for 20 minutes, and 171 
kept at 4°C until use. Cells were then treated and viewed as in [38]. 172 
 173 
Western blot analysis 174 
A427 and C2C12 cells were analyzed for ALDH3A1 expression using Western blot analysis [38]. 175 
Polyclonal anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or monoclonal anti-aldehyde 176 
dehydrogenase (ALDH) 3A1 antibodies were used. 177 
 178 
ELISA analysis 179 
TNF-α content was evaluated in the culture medium of A427 cells by the Enzyme Linked Immuno 180 
Sorbent Assay (Invitrogen Corporation, Frederick, MD, USA). 181 
 182 
Real time PCR analysis 183 
PPARα mRNA content was examined in A427cells treated (sample) or not (control) with PUFAs 184 
for 24 hours. 185 
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Total RNA was extracted by using the TRI reagent (Sigma-Aldrich, St. Louis, MO, USA). Real-186 
time PCR was performed with single-stranded cDNA prepared from total RNA (1 µg) using a High-187 
Capacity cDNA Archive kit (Applied Bio Systems, Foster City, CA). 188 
The forward and reverse primers were designed using Beacon Designer® software (Bio-Rad, 189 
Hercules, CA). Twenty-five microliters of a PCR mixture containing cDNA template equivalent 40 190 
ng of total RNA, 5 pmoles each of forward and reverse primers, and 2× IQ SYBR Green SuperMix 191 
(Bio-Rad, Hercules, CA) were amplified using an iCycler PCR instrument (Bio-Rad, Hercules, CA) 192 
with an initial denaturation at 95°C for 3 min, followed by 35-40 cycles at 95°C for 30 s, annealing 193 
at 52°C for 40 s, extension at 72°C for 40 s. Each sample was tested in duplicate, and threshold 194 
cycle (Ct) values were averaged from each reaction. The change in expression was defined as that 195 
detected in the A427 cells treated with PUFAs versus that detected in the control cells, calculated as 196 
2-∆∆Ct, where ∆Ct = Ctsample - CtGAPDH and ∆∆Ct = ∆Ctsample - ∆Ctcontrol. 197 
 198 
 199 
Lipid peroxidation in A427 cells 200 
Malondialdehyde was measured in HPLC according to the method of Nielsen et al [39], with slight 201 
modifications. Briefly, aliquots of cell medium were mixed (volume/volume) with 0.6% (w/v) 202 
aqueous solution of thiobarbituric acid (TBA). The mixture was acidified with 1/20 volume of 203 
100% (w/v) trichloroacetic acid and heated at 100°C for 1 hour. The samples were then cooled in 204 
ice and centrifuged at 13000 g for 5 minutes. Aliquots of 50 µl of the supernatant were injected into 205 
the HPLC system. 206 
The HPLC system was equipped with a Novapak C18 4um 3.9x150 mm column. The elution was 207 
isocratic. The mobile phase consisted of a mixture of a 10 mM potassium dihydrogen phosphate 208 
solution adjusted at pH 6.8 with 1M KOH and methanol in ratio 60/40. The flow rate was 1 ml/min. 209 
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Detection was performed by a spectrofluorometer at 532 nm ex/553 nm em. The peak of the MDA-210 
TBA adduct was well resolved at baseline and its retention time in our conditions was 4.8 min. 211 
Identification and quantification of MDA concentration in the samples was performed by 212 
comparison to the chromatograms of various concentrations of standard MDA sodium salt, 213 
synthesized by Dr Bruno Tasso, according to Nair et al [40], treated in the same way as the samples. 214 
The lowest tested concentration of standard that was still quantifiable was 0.125 µM. 215 
 216 
Detection of putative peroxisome proliferator response element (PPRE) 217 
The presence of the putative PPRE sequence in genes encoding fast isoforms of myosin heavy chain 218 
(MyHC) was evaluated with the NHR SCAN software package. 219 
 220 
Statistical analysis 221 
All data are expressed as means ± S.D. Differences between means were assessed by analysis of 222 
variance followed by the post-hoc Newman-Keuls test. 223 
 224 
RESULTS 225 
The effect of PUFAs on growth and viability of lung cancer cells is reported in Figure 1. Exposing 226 
A427 cells to PUFAs caused a dose-dependent decrease in cell growth that was more marked for n-227 
3 PUFAs (panel A): 10 or 50 µM EPA plus DHA reduced cell numbers by 22% and 38%, 228 
respectively, whereas AA only affected A427 cell numbers significantly (-20%) at the highest 229 
concentration used. Neither n-3 nor n-6 PUFAs significantly induced either necrosis (panel B) or 230 
apoptosis (panel C). 231 
Lipid peroxidation (Figure 2) was measured in the culture medium of A427 cells exposed to PUFAs 232 
and expressed as the production of MDA. A similar and significant increase was observed in cells 233 
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exposed to EPA plus DHA or to AA (about +40% or +70%, in the presence of 10 or 50 µM PUFAs, 234 
respectively). 235 
Figure 3 panel A shows that both concentrations of EPA+DHA decreased TNFα content in the 236 
culture medium of A427 cells, whereas only the highest concentration of AA decreased this 237 
cytokine. Figure 3 panel B reports that PPARα mRNA was increased in A427 cells treated with 238 
both 50 µM PUFAs, being the highest increase in A427 cells treated with EPA+DHA. 239 
Culture medium conditioned for 24 h by A427 cells, in the presence or absence of PUFAs, was used 240 
to grow murine muscle C2C12 cells, with the aim of investigating its effect on muscle cell 241 
differentiation. No significant change in C2C12 viability was evidenced by analyzing LDH activity 242 
in the culture medium, at any of the experimental conditions investigated (data not shown). 243 
Figure 4 shows that C2C12 cells grown in medium conditioned by A427 cells, in the absence of 244 
PUFAs, showed no production of myosin and no myotube formation, unlike cells maintained in 245 
differentiation medium (Tdiff). Conversely, in C2C12 cells grown in medium conditioned by A427 246 
cells in the presence of both n-3 and n-6 PUFAs, myosin production and myotube formation both 247 
occurred, the most significant effect being evident in cells grown in medium conditioned in the 248 
presence of 50 µM EPA plus DHA. 249 
To investigate the role of lipid peroxidation products in reversing the anti-differentiation effect of 250 
lung cancer cells on C2C12 cells, HHE and HNE were directly added to C2C12 cells grown in 251 
medium conditioned by A427 cells, in the absence of n-3/n-6 PUFAs. Figure 5 shows the effect of 252 
aldehyde administration on C2C12 cell viability: only HHE, at either of the concentrations used, 253 
significantly increased LDH release. 254 
Figure 6 shows that both myosin content and myotubes in C1C12 increased in a dose-dependent 255 
manner, in C2C12 cells exposed for 4 days to aldehydes, the strongest effect being observed in cells 256 
exposed to 5 µM HNE. 257 
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Western blot analysis of ALDH3A1 protein content showed that neither A427 nor C2C12 cells 258 
express this enzyme, which is significant in metabolizing aldehydes derived from lipid peroxidation 259 
(Figure 7). 260 
Table 1 reports the analysis of the putative PPRE motif in fast isoforms of myosin heavy chain 261 
(MyHC). The NHR SCAN software evidenced the putative presence of the PPRE consensus 262 
sequence in both exons /introns of IIa, IIb, IId/x genes, but not in the promoter regions. 263 
 264 
DISCUSSION 265 
In this research the anti-cachectic effect of both n-3 and n-6 PUFAs was investigated alongside with 266 
the possibility that this effect can be mediated by their major aldehydic products of lipid 267 
peroxidation, HHE and HNE, and by their anti-inflammatory properties. Aldehyde products derived 268 
from the lipid peroxidation of PUFAs have been shown to exert both regulatory and detrimental 269 
effects on several cell functions, mainly depending on their cellular concentration. When produced 270 
at physiological or low levels, lipidic aldehydes can act as signalling molecules targeting specific 271 
pathways, including tyrosine kinase signalling and the adaptive response mediated by Nrf2, AP-1, 272 
PPARs and NFkB [41]. Conversely, high intracellular levels of lipidic aldehydes are responsible for 273 
cytotoxic or cytostatic effects [42,43]. 274 
Among aldehydes derived from lipid peroxidation, α,β-unsaturated aldehydes are those that have 275 
been studied in most depth; they are the most important molecular mediators of the effects of both 276 
n-3 and n-6 PUFAs. 277 
The “in vitro” model of cancer cachexia used in this research enabled both the effect of PUFA 278 
administration on pro-cachectic activity of human lung cancer cells, and the effects of culture 279 
medium conditioned by cancer cells in the presence or not of PUFAs on muscle cell differentiation, 280 
to be investigated. 281 
The most important finding of the study is that both PUFA families, n-3 and n-6, decreased the 282 
proliferation of human lung cancer cells, and were able to prevent the inhibition of muscle cell 283 
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differentiation induced by lung cancer cells. The observation that AA decreased cancer cell 284 
proliferation disagrees with the results of certain other studies [44-46], but confirms previous 285 
studies by the present research group evidencing that this n-6 PUFA suppresses the growth of well 286 
differentiated human lung tumour cells A549 and of rat hepatocarcinoma cell lines [47-50]. The 287 
inhibitory effect of AA on cancer cell proliferation has been inversely related to the ability of cells 288 
to metabolize aldehydic products of lipid peroxidation, in particular to the expression of aldehyde 289 
dehydrogenase 3A1 (ALDH3A1) [49]. For this reason, in this research the protein content of 290 
ALDH3A1 was evaluated in A427 and C2C12 cells, neither of which expresses this enzyme. The 291 
lack of this enzyme in A427 cells could be important in maintaining the high level of lipid 292 
peroxidation products observed after n-3 or n-6 PUFA supplementation, and, in consequence, might 293 
be the explanation for their effect on both cell proliferation and pro-cachectic properties of A427 294 
cells. At the same time, the poor ability of C2C12 cells to catabolise aldehydes might be crucial in 295 
maintaining aldehyde levels that are able to induce muscle cell differentiation. In fact, unlike free 296 
radicals, which have a very short half-life, HNE and other aldehydes deriving from lipid 297 
peroxidation can diffuse from the site where they are produced and modulate signalling pathways in 298 
other cells. 299 
HNE has been reported to induce cell differentiation in human leukemic HL-60 cells and in murine 300 
erythroleukemia MEL cells [32], the pathways proposed being different: translocation of PKC, 301 
formation of adducts with Heat Shock 60 kDa Protein 1 [51], and inhibition of telomerase activity 302 
[52]. In the light of these observations, the supposed involvement of lipid peroxidation products in 303 
mediating the anti-cachectic properties of lung cancer cells was investigated. Exposing C2C12 304 
muscle cells, maintained in medium conditioned by A427 cells in the absence of PUFAs, to HNE or 305 
to HHE induced the expression of myosin and the formation of myotubes, indicating the ability of 306 
both lipid peroxidation products to stimulate muscle cell differentiation, counteracting the inhibitory 307 
effect of medium conditioned by lung cancer cells. These results show, firstly, that HHE also 308 
possesses differentiation properties, and secondly that both the major lipid peroxidation products of 309 
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n-3 and n-6 PUFAs can block the anti-differentiation effect of lung cancer cells and induce 310 
expression of myosin in murine muscle cells. 311 
The lipid peroxidation products can induce muscle cell differentiation indirectly by blocking the 312 
anti-differentiation effect of TNFα produced and released by cancer cells, and directly by affecting 313 
myosin expression, as evidenced by treatment of C2C12 cells with HHE and HNE. The first 314 
mechanism contributing to C2C12 cell differentiation, i.e. the decrease TNFα content in culture 315 
medium of A427 cells, can be explained by the increased PPARα expression, induced by PUFAs or 316 
their lipid peroxidation products, including HHE and HNE. This statement is in agreement with our 317 
previous researches, showing that PUFAs were able to induce PPARs, and, as consequence, to 318 
decrease tumour cell proliferation and cytokine content in cell culture medium [49,53,54]. 319 
It has been shown that HNE acts as an intracellular agonist of peroxisome proliferator-activated 320 
receptors (PPARs) and that it is thus involved in regulating several intracellular pathways [55,56]. 321 
PPARs are nuclear transcription factors that, after ligand binding, heterodimerize with RXRα 322 
(PPARα/RXRα) and bind to the consensus sequence named PPRE (Peroxisome proliferator 323 
response element) in the target genes.  324 
 325 
The PPRE motif consist of 2 half-sites (AGGTCA N AGGTCA) with an interspacing nucleotide 326 
(DR-1, direct repeat 1) [57]. Based on these observations, the presence of putative PPRE sequences 327 
in genes encoding fast isoforms of myosin heavy chain (MyHC) was investigated. The 328 
bioinformatic approach used in this preliminary analysis evidenced the presence of putative PPRE 329 
in both exons and intron of genes encoding fast myosin heavy chains, but not in the promoter 330 
region. This suggests that the increased production of myosin observed in C2C12 cells, grown in 331 
medium conditioned by A427 cells in the presence of PUFAs, and in the same cells directly 332 
exposed to HHE or HNE, could be PPAR-dependent.  333 
Taken as a whole, these results demonstrate the ability of both n-3 and n-6 PUFAs, and of their 334 
aldehydic lipid peroxidation products HHE and HNE, to decrease TNFα release and to prevent the 335 
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decrease of myosin expression and myotube formation that is determined by culturing C2C12 336 
muscle cells in the presence of medium conditioned by lung tumour cells. The lower induction of 337 
differentiation observed in C2C12 cells treated with HHE in comparison with C2C12 cells grown in 338 
culture medium of A427 cells treated with EPA+DHA can be due to the fact that the treatment with 339 
n-3 PUFAs caused, other that the production of lipid aldehydes, a decrease of TNFα. This decrease 340 
was higher than in the case of A427 cells treated with AA, and this difference could explain the 341 
higher differentiation effect induced by EPA+DHA respect to AA.  342 
This finding could represent an important starting point to investigate in greater depth the 343 
possibility of designing therapeutic protocols using natural dietary substances, such as n-3 and n-6 344 
PUFAs, to both directly reduce the growth of cancer cells, and reduce their ability to decrease 345 
myosin synthesis and differentiation in muscle cells, which occurs in cancer cachexia. 346 
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FIGURE CAPTIONS 528 
 529 
Figure 1. Effect of n-3 or n-6 PUFAs on growth and viability of human lung cancer cells A427. 530 
Data are means ± S.D. from 4 experiments. For each panel, means with different letters are 531 
significantly different from one another (p<0.05) as determined by analysis of variance followed by 532 
post-hoc Newman-Keuls analysis. 533 
C, control cells; E + D 10, cells treated with 10 µM EPA + DHA (1.5:1 ratio); E + D 50, cells 534 
treated with 50 µM EPA + DHA (1.5:1 ratio); AA 10; cells treated with 10 µM AA; AA 50; cells 535 
treated with 50 µM AA. 536 
 537 
Figure 2. Lipid peroxidation in culture medium of human lung cancer cells A427 treated or not with 538 
n-3 or n-6 PUFAs for 24 hours. 539 
Data are means ± S.D. from 4 experiments and are expressed as percentage of control value taken 540 
as 100. Means with different letters are significantly different from one another (p<0.05) as 541 
determined by analysis of variance followed by post-hoc Newman-Keuls analysis. 542 
MDA, malondialdehyde; C, control cells; E + D 10, cells treated with 10 µM EPA + DHA (1.5:1 543 
ratio); E + D 50, cells treated with 50 µM EPA + DHA (1.5:1 ratio); AA 10; cells treated with 10 544 
µM AA; AA 50; cells treated with 50 µM AA. 545 
 546 
Figure 3. TNFα (panel A) and PPARα (panel B) in culture medium of A427 cells treated or not with 547 
n-3 or n-6 PUFAs for 24 hours and in A427 cells, respectively. 548 
Data are means ± S.D. from 4 experiments and are expressed as percentage of control value taken 549 
as 100. For each panel, means with different letters are significantly different from one another 550 
(p<0.05) as determined by analysis of variance followed by post-hoc Newman-Keuls analysis. 551 
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C, control cells; E + D 10, cells treated with 10 µM EPA + DHA (1.5:1 ratio); E + D 50, cells 552 
treated with 50 µM EPA + DHA (1.5:1 ratio); AA 10; cells treated with 10 µM AA; AA 50; cells 553 
treated with 50 µM AA. 554 
 555 
Figure 4. Myosin content evidenced by immunofluorescence in C2C12 murine myoblasts grown in 556 
culture medium conditioned by human lung cancer cells A427, in the presence or absence of 557 
PUFAs. 558 
Tdiff, cells maintained in medium B; none, cells grown in culture medium conditioned by A427 559 
cells in the absence of PUFAs; E + D 10, cells treated with 10 µM EPA + DHA (1.5:1 ratio); E + D 560 
50, cells treated with 50 µM EPA + DHA (1.5:1 ratio); AA 10; cells treated with 10 µM AA; AA 561 
50; cells treated with 50 µM AA. 562 
 563 
Figure 5. Effect of HHE and HNE on viability of C2C12 murine myoblasts grown in culture 564 
medium conditioned by human lung cancer cells A427 in the absence of PUFAs. 565 
Data are means ± S.D. from 4 experiments. Means with different letters are significantly different 566 
from one another (p<0.05) as determined by analysis of variance followed by post-hoc Newman-567 
Keuls analysis. 568 
Tdiff, cells maintained in medium B; none, cells grown in culture medium conditioned by A427 569 
cells in the absence of PUFAs; HHE 1, cells grown in culture medium conditioned by A427 cells in 570 
the absence of PUFAs and treated with 1 µM HHE; HHE 5, cells grown in culture medium 571 
conditioned by A427 cells in the absence of PUFAs and treated with 5 µM HHE; HNE 1, cells 572 
grown in culture medium conditioned by A427 cells in the absence of PUFAs and treated with 1 573 
µM HNE; HNE 5, cells grown in culture medium conditioned by A427 cells in the absence of 574 
PUFAs and treated with 5 µM HNE (for treatment details see Materials and Methods). 575 
 576 
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Figure 6. Myosin content evidenced by immunofluorescence in C2C12 murine myoblasts grown in 577 
culture medium conditioned by human lung cancer cells A427 in the absence of PUFAs and treated 578 
with HHE and HNE. 579 
Tdiff, cells maintained in medium B; none, cells grown in culture medium conditioned by A427 580 
cells in the absence of PUFAs; HHE 1, cells grown in culture medium conditioned by A427 cells in 581 
the absence of PUFAs and treated with 1 µM HHE; HHE 5, cells grown in culture medium 582 
conditioned by A427 cells in the absence of PUFAs and treated with 5 µM HHE; HNE 1, cells 583 
grown in culture medium conditioned by A427 cells in the absence of PUFAs and treated with 1 584 
µM HNE; HNE 5, cells grown in culture medium conditioned by A427 cells in the absence of 585 
PUFAs and treated with 5 µM HNE (for treatment details see see Materials and Methods). 586 
 587 
Figure 7. Aldehyde dehydrogenase 3A1 protein content in human lung cancer cells A427 and in 588 
C2C12 murine myoblasts. 589 
Lane 1, A427 cells; lane 2, C2C12 cells; C+, positive control. 590 
TABLE 1 –PUTATIVE PPRE MOTIF IN GENES ENCODING FAST ISOFORMS OF MYOSIN 
HEAVY CHAIN  
 
MyHC Gene I.D. PUTATIVE PPRE MOTIF 
  Promoter region Exons / Introns 
    bp 
IIa 17882 Not present 1 DR1 (intron 3) 3543 -3555 
   1 DR1 (exon 4) 4032 - 4044 
   1 DR1 (intron 16) 11674 - 11686 
   1 DR1 (exon 19) 14111 - 14123 
     
IIb 17884 Not present 1 DR1 (intron 1) 229 - 241 
   1 DR1 (intron 4) 3890 - 3902 
   1 DR1 (intron 15) 10814 - 10826 
   1 DR1 (exon 27) 16059 - 16071 
     
IId/x 17879 Not present 1 DR1 (intron 5) 2502 - 2514 
   1 DR1 (intron 9) 5309 - 5321 
   2 DR1 (intron 15) 7975 - 7987 
    8606 - 8618 
 
   MyHC, myosin heavy chain 
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